ClinicaliQ Trial Snapshot
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Active Not Recruiting • Phase III • Oncology • NCT06016738.
- Palazestrant versus standard hormone therapy in advanced breast cancer that's progressed on previous endocrine treatment plus CDK4/6 inhibitor.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor. Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma Interventions: Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane Lead Sponsor: Olema Pharmaceuticals, Inc. Planned Enrollment: 510 participants